Name recognition and “familiarity” with Novo Nordisk’s oral Wegovy have significantly contributed to its rapid market uptake, particularly in its competition against Lilly’s oral GLP-1 treatment, Foundayo. This insight comes from Spherix analyst Jim Hickey, who regularly conducts surveys with healthcare professionals prescribing these treatments. The data indicates that physicians’ existing awareness of Wegovy plays a crucial role in their prescribing habits, which may lead to a preference for Novo’s product over newer entrants.
This trend underscores the importance of brand familiarity in the pharmaceutical landscape, especially in therapeutic areas where competition is intensifying. As oral GLP-1 therapies gain traction, understanding the drivers behind physician preferences will be essential for companies looking to establish or maintain a competitive edge. The implications for regulatory, QA/QC, and sourcing professionals are clear: fostering brand recognition and trust can be as critical as the efficacy of the product itself.
Open the full market picture for your next decision →
